Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SP110 nuclear body protein is a leukocyte-specific transcription factor and nuclear body component implicated in the regulation of immune responses. It is primarily active in leukocytes and spleen, helping control gene activity essential for the immune system. SP110 acts as a transcriptional coactivator, including for nuclear hormone receptors and retinoic acid response elements. It is part of the SP100/SP140 nuclear body protein family. Mutations can lead to disorders such as hepatic veno-occlusive disease with immunodeficiency, marked by impaired immune function and recurring infections. Variants may also influence risk of neurodegenerative diseases like ALS and spinal muscular atrophy. Several isoforms exist due to alternative splicing, which may alter protein function and disease susceptibility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SP110 nuclear body protein (SP110).